Novavax appoints chief medical officer
Mark Thornton joins US biopharma firm from GenVac
Before joining the US biopharmaceutical firm, Thornton was a medical officer in the US Navy and the US Food and Drug Administration's (FDA) immunology and infectious diseases branch and division of therapeutic biologic oncology products; chief medical officer of ZioPharm Oncology and managing director of clinical and regulatory affairs at Angiotech Pharmaceuticals. Most recently, he was senior vice president of product development at GenVec.
Rahul Singhvi, chief executive of Novavax, said: ‘Mark is a talented clinical pharmacologist and epidemiologist with more than 20 years of experience in the design and execution of clinical trials and the development of novel vaccines and therapeutics. He spent more than six years as a medical officer at the FDA's centres for drugs and biologics evaluation and research and has a keen understanding of the need for innovative new drugs and what is required to obtain their approvals. We welcome his leadership as we work toward regulatory approval of our vaccines to prevent pandemic and seasonal flu, respiratory syncytial virus and other infectious diseases.’
You may also like
Research & Development
Alternating vaccines trial expands to include two additional vaccines
Volunteers, who will have received either the Oxford-AstraZeneca, or Pfizer vaccine, will be randomly allocated to receive either the same vaccine for their second dose, or a dose of the COVID-19 vaccines produced by Moderna or Novavax
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
